Race Oncology Limited
RAONF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -1.80 | -0.22 | -5.46 |
| FCF Yield | -1.62% | 0.15% | -0.46% | -2.79% |
| EV / EBITDA | -63.87 | 1,100.71 | -35.63 | -96.37 |
| Quality | ||||
| ROIC | -28.38% | 3.75% | -43.38% | -13.25% |
| Gross Margin | 67.59% | 92.77% | 7.58% | 74.73% |
| Cash Conversion Ratio | 0.97 | 1.14 | 0.17 | 1.44 |
| Growth | ||||
| Revenue 3-Year CAGR | 167.48% | 175.93% | 169.04% | 164.00% |
| Free Cash Flow Growth | -1,001.62% | 141.02% | 82.94% | -70.44% |
| Safety | ||||
| Net Debt / EBITDA | 2.87 | -57.13 | 2.14 | 4.74 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -157.77 | -114.31 | -257.65 | -126.41 |